Weyer Jacqueline, Rupprecht Charles E, Mans Janet, Viljoen Gerrit J, Nel Louis H
University of Pretoria, Department of Microbiology and Plant Pathology, Pretoria 0002, South Africa.
Vaccine. 2007 May 22;25(21):4213-22. doi: 10.1016/j.vaccine.2007.02.084. Epub 2007 Mar 22.
Modified vaccinia virus Ankara (MVA) has become a vaccine vector of choice for recombinant vaccine development. A MVA-based rabies vaccine would be advantageous for use as a vaccine for dogs (and wildlife), particularly if it proves innocuous and efficacious by the oral route. Here, the generation and immunological testing of a recombinant MVA expressing a rabies virus glycoprotein gene is described. In a murine model, higher dosages of recombinant MVA were needed to induce equivocal immune responses as with Vaccinia Copenhagen or Vaccinia Western Reserve recombinants, when administered by a parenteral route. The MVA recombinant was not immunogenic or efficacious when administered per os in naïve mice. The ability of the recombinant MVA to induce anamnestic responses in dogs and raccoons was also investigated. Recombinant MVA boosted humoral immune responses in these animals when administered peripherally, but not when administered orally.
安卡拉痘苗病毒（MVA）已成为重组疫苗开发中首选的疫苗载体。基于MVA的狂犬病疫苗对于用作犬类（和野生动物）疫苗将具有优势，特别是如果经口服途径证明其无害且有效。在此，描述了表达狂犬病病毒糖蛋白基因的重组MVA的构建及免疫学检测。在小鼠模型中，当通过非肠道途径给药时，与哥本哈根痘苗病毒或西储痘苗病毒重组体相比，需要更高剂量的重组MVA才能诱导出不明确的免疫反应。重组MVA在未接触过抗原的小鼠经口给药时无免疫原性且无效。还研究了重组MVA在犬和浣熊中诱导回忆反应的能力。当外周给药时，重组MVA可增强这些动物的体液免疫反应，但经口给药时则不然。
